Across TCGA pan-cancer cohorts, ASIC3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASIC3 data layer compared with 27 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ASIC3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASIC3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LIHC, KICH, and KIRC are the cancer types where ASIC3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.